EOS imaging receives Chinese FDA marketing approval


EOS imaging has received approval from the China Food and Drug Administration (CFDA) to market the EOS system in China.

The EOS system can now be marketed in 51 countries.

The EOS system is in clinical use in several markets in the Asia Pacific region, including Hong Kong, Singapore, Japan, Australia and Vietnam. In addition, an EOS equipment is installed in a Shanghai hospital where it is being used for clinical studies.

According to a company release, the CFDA approval will allow EOS to develop commercial activity in this major market, which includes more than 1,200 top grade (3A and 3B) hospitals, within an established distribution partnership.

Experience with the EOS system will be shared with Chinese physicians by several French radiologists and orthopaedic surgeons during the upcoming Jishuitan Orthopedics Forum in Beijing, April 22-24, 2016. The meeting is a biennial, multi-disciplinary event focused on orthopaedics, attracting more than 3,000 attendees from over 1,200 hospitals.

This year, the meeting includes special sessions for Chinese-French exchange across multiple areas of orthopaedic treatment, including spine, joint articulation, paediatrics and radiology.

Marie Meynadier, chief executive officer of EOS imaging, says, “We are excited to begin commercial activities in China with our local partner, where there is already positive awareness and demand for the EOS system.”